Trade, Competition & RegulationPractice area · 08
Life Sciences, Healthcare and
Pharmaceutical Regulation
Internationally focused counsel for Life Sciences, Healthcare & Pharma Regulation matters—framing the governing law, commercial decision and jurisdiction-specific inputs before selecting a route.
The starting point
Frame the immediate regulatory
question
Different Bangladesh frameworks may be relevant to different parts of an operating model. These prompts are general information for scoping a conversation; they are not a classification, licence, compliance, competition-risk or transaction determination.
Map the regulated activity
Identify whether the immediate question concerns a medicine, pharmacy, private facility, professional role or more than one of these. Product, facility, supply-route and people-related facts can engage distinct Bangladesh frameworks.This is general information, not a classification, licence or compliance determination.
Plan the route to market or operating change
DGDA describes a remit covering medicines-related activities including raw materials, finished drugs, import, export, sales and pricing. The facts behind a proposed manufacture, supply route, sale or operating change therefore need to be identified carefully.Current requirements and procedure depend on the facts and should be checked against official sources and specific advice.
Test the transaction and market-conduct perimeter
An acquisition, control change, supply arrangement or exclusivity provision may require the relevant Bangladesh regulatory and competition questions to be identified. The Competition Act addresses commercial activity in goods and services and includes acquisition and combination in its statutory framework.No conclusion on competition risk, notification, approval or transaction outcome should be drawn from this page.
Source-attributed matters
Selected TRW deal
record
This limited firm-published record is presented as a labelled source reference. It is not evidence of Bangladesh law, a Bangladesh matter, foreign-law capability, an outcome or a broader client relationship.
Firm-published transaction record
The firm-published source record attributes this matter to TRW and states: “Client: A UAE-based healthcare provider” and “Transaction: Acquisition of a hospital chain in the UK for $300 million.” No independent verification has been identified.Firm-published transaction record — no independent verification.Private Equity Expertise by TRW Law FirmA focused conversation
Regulatory issue-scoping
lenses
The following topics organise high-level questions for this regulated perimeter. They are editorial workstreams, not statements that TRW provides a particular service or a promise of a regulatory, commercial or legal outcome.
Product and classification orientation
Frame the product, product category, intended market and relevant regulatory pathway before operational decisions, without stating a classification, registration eligibility or approval status.Medicines supply-chain and market-access questions
Identify facts connected with manufacture, raw materials, finished-drug import, distribution, sale, export and pricing topics reflected in DGDA’s published remit, without inferring market entry, registration or pricing approval.Drug licensing and pharmacy operations
Separate questions about drug licences, retail or wholesale operating models and pharmacist-related controls from unverified application steps, timelines or compliance assurances.Private facilities, clinics and laboratories
Distinguish facility-level questions involving private clinics, diagnostics and laboratories from product regulation, without making a finding on licensure, accreditation, clinical safety, patient rights or medical negligence.Professional and workforce regulation
Identify whether medical, dental or pharmacy registration and institutional-recognition questions need to be scoped, without confirming professional status, providing employment advice or offering clinical advice.Commercial arrangements and competition
Identify potential distribution, supply, exclusive-arrangement and acquisition or control questions that may require competition-law review in a regulated market, without reaching a competition, notification or transaction conclusion.Cross-border regulatory coordination
Organise Bangladesh-facing facts where a foreign manufacturer, investor, supplier or provider is involved, without presenting foreign-law advice, global coverage or cross-border outcomes.Bangladesh context
Bangladesh regulatory
context
These public-source signals provide institutional and statutory context only. They do not establish what applies to a particular product, facility, person, arrangement or transaction, and current law and procedure require case-specific confirmation.
Drug regulation
DGDA describes itself as Bangladesh’s drug regulatory authority and states that its remit includes prevailing drug regulations and activities relating to raw and packing materials, finished drugs, import, export, sales and pricing.Read sourcePrivate-facility context
The Medical Practice and Private Clinics and Laboratories (Regulation) Ordinance, 1982 is titled as a law to regulate medical practice and the functioning of private clinics and laboratories. The DGHS Hospital Services Management portal presents private-facility registration and public listings.Read sourcePharmacy-practice context
The Pharmacy Ordinance, 1976 establishes the Pharmacy Council to regulate pharmacy practice and lists functions including maintaining registers and registering pharmacists. The Council portal presents registration, renewal and verification services.Read sourceQuestions, not prescriptions
What may
matter.
These answers are general information. The applicable route depends on the facts, documents and current legal position.
Which authority does Bangladesh identify as its drug regulatory authority?
What is the legal context for private clinics and laboratories?
What does the Pharmacy Council framework cover?
Begin with context
Start with high-level regulatory
context
For a confidential consultation, share only a high-level, non-sensitive outline of the organisation, activity, Bangladesh and other jurisdictional touchpoints, and decision timetable. Do not send patient records, personal health information, adverse-event reports, trade secrets or detailed transaction documents through an unsecured form or ordinary email.
- The Drugs (Control) Ordinance, 1982 — Bangladesh Laws
- Directorate General of Drug Administration — Official website
- The Medical Practice and Private Clinics and Laboratories (Regulation) Ordinance, 1982 — Bangladesh Laws
- The Pharmacy Ordinance, 1976 — Bangladesh Laws
- Bangladesh Medical and Dental Council Act, 2010 — Bangladesh Laws
- Competition Act, 2012 — Bangladesh Laws
- Hospital Services Management — Directorate General of Health Services
- Pharmacy Council of Bangladesh — Official Automation Portal
- Private Equity Expertise by TRW Law Firm
- TRW Law Firm — Our Practice Areas